Want to see BOLD full AI Analyst Report?
Boundless Bio Inc. (BOLD) AI Stock Analysis
Boundless Bio Inc.
(NASDAQ:BOLD)
The score is held down primarily by very weak financial performance (no revenue, sustained large losses, and heavy ongoing cash burn), which outweighs the moderately positive technical setup. Corporate events are mixed: the Serapha merger and financing can reset the company’s trajectory, but the substantial dilution/control shift and restructuring add meaningful risk. Valuation is also constrained by losses and the absence of dividend support.
Boundless Bio Inc. (BOLD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $54.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 163.53K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.16
- Revenue Growth
- ―
- EPS Growth
- 1.11%
- Country
- US
- Employees
- 28
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Boundless Bio Inc. Business Overview & Revenue Model
Company Description
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromoso...
How the Company Makes Money
Boundless Bio is a clinical-stage biotech and, as such, its revenue model is primarily not based on product sales. null
Boundless Bio Inc. Financial Statement Overview
Summary
Financial profile is very weak: zero revenue across the provided history with large, persistent operating and net losses. Cash flow is deeply negative (TTM operating cash flow about -$56M; free cash flow about -$57M), implying ongoing external financing needs. The main offset is improved balance-sheet structure versus earlier years with positive equity in recent periods, though equity has contracted materially from 2024 to TTM.
Income Statement
6Very NegativeBalance Sheet
42NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -901.00K | -1.25M | -1.09M | 0 | 0 | 0 |
| EBITDA | -61.85M | -56.95M | -64.28M | -48.48M | -44.96M | -24.53M |
| Net Income | -64.01M | -58.20M | -65.36M | -49.43M | -45.90M | -25.21M |
Balance Sheet | ||||||
| Total Assets | 73.74M | 157.06M | 206.41M | 129.89M | 76.83M | 113.72M |
| Cash, Cash Equivalents and Short-Term Investments | 72.63M | 107.58M | 152.11M | 120.75M | 66.72M | 73.03M |
| Total Debt | 0 | 49.03M | 47.63M | 2.19M | 5.18M | 377.00K |
| Total Liabilities | 7.77M | 58.41M | 55.77M | 256.98M | 158.53M | 151.91M |
| Stockholders Equity | 65.98M | 98.65M | 150.64M | -127.08M | -81.70M | -38.19M |
Cash Flow | ||||||
| Free Cash Flow | -56.73M | -47.21M | -63.38M | -47.49M | -40.66M | -25.28M |
| Operating Cash Flow | -56.25M | -46.66M | -60.84M | -46.85M | -39.60M | -23.25M |
| Investing Cash Flow | 61.11M | 37.80M | -26.10M | -38.26M | 16.13M | -59.28M |
| Financing Cash Flow | 97.00K | 141.00K | 89.82M | 97.90M | 126.00K | 105.53M |
Boundless Bio Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Negative. The current price of 2.40 is below the 20-day moving average (MA) of 2.43, below the 50-day MA of 2.63, and above the 200-day MA of 1.93, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.77 is Neutral, neither overbought nor oversold. The STOCH value of 24.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLD.
Boundless Bio Inc. Risk Analysis
Boundless Bio Inc. disclosed 99 risk factors in its most recent earnings report. Boundless Bio Inc. reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBoundless Bio Inc. Peers Comparison
Overall Rating
- BOLD48Neutral
ALXO42Neutral
CLGN41Neutral
ALGS39Underperform
PLUR27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| BOLD | 48Neutral | $54.14M | -0.84 | -70.89% | ― | ― | 1.11% |
| ALXO | 42Neutral | $178.38M | -1.20 | -90.30% | ― | ― | 48.20% |
| CLGN | 41Neutral | $7.77M | -0.45 | -215.58% | ― | -86.76% | 16.63% |
| ALGS | 39Underperform | $29.66M | -0.69 | -160.72% | ― | 893.01% | 41.74% |
| PLUR | 27Underperform | $16.02M | -0.50 | 144.63% | ― | -23.95% | 30.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BOLD | Boundless Bio Inc. | 2.40 | 1.14 | 90.48% | |
| PLUR | Pluri Inc. | 1.23 | -2.02 | -62.15% | |
| CLGN | CollPlant Biotechnologies Ltd. | 4.23 | -17.57 | -80.60% | |
| ALXO | Alx Oncology Holdings, Inc. | 1.36 | 0.18 | 15.25% | |
| ALGS | Aligos Therapeutics, Inc. | 5.02 | -2.08 | -29.30% |
Boundless Bio Inc. Corporate Events
Boundless Bio Amends Merger Agreement with Serapha Bio
PositiveOn June 22, 2026, Boundless Bio, Inc. agreed to merge its wholly owned subsidiary Boulder Merger Sub Corp. into Serapha Bio, Inc., with Serapha to become a wholly owned subsidiary of Boundless Bio, and on August 28, 2026, the parties executed an amen...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026